BACKGROUND: @entity1652 ( @entity1652 ) has evolved from devic's classical description to a broader disease spectrum, from monophasic illness to a @entity221 with multiple recurrences, disease confined to optic nerve and spinal cord to now brain stem, cerebrum and even @entity2744 due to hypothalamic involvement. OBJECTIVES: To report, the epidemiological characteristics, clinical presentations, recurrence rate, treatment and response to therapy in 26 @entity1 with @entity1652 and @entity1652 spectrum disorder among the Indian population. METHODS: We performed observational, retrospective analysis of our prospectively maintained data base of @entity1 with @entity1652 , longitudinally extensive @entity5697 during the period of January 2003-December 2012 who satisfied the national @entity15 society (NMSS) task force criteria for diagnosis of @entity1652 and @entity1652 spectrum disorder. RESULTS: There were 26 @entity1 (female: male, 21:5), the mean age of onset of symptom was 27 years (range 9-58, standard deviation = 12). Twenty-one @entity1 (80%) fulfilled NMSS criteria for @entity1652 while rest 5 @entity1 (20%) were considered as @entity1652 spectrum disorder. Seven @entity1 (27%) had a monophasic illness, 19 @entity1 (73%) had a @entity221 with recurrences. The Median recurrence rate was 4/ @entity1 in the polyphasic group. 13 (50%) @entity1 were tested for @entity3951 antibody, 8 (61%) were positive while 5 @entity1 (39%) were negative. All @entity1 received intravenous @entity1667 , 9 @entity1 (35%) required further treatment for @entity697 in view of unresponsiveness to @entity230 . Thirteen @entity1 (50%) received disease-modifying agents for recurrences. Mean duration of follow-up was 5 years. All @entity1 had a good outcome (modified Rankin scale, <3) except one who had poor visual recovery. CONCLUSION: @entity1652 / @entity1652 spectrum disorder is @entity17 with female predominance, polyphasic course, @entity4685 being most common event although brain stem involvement is not uncommon with @entity1652 antibody positivity in 60% @entity1 , confirms the literature data.

@entity1652 and XXXX optica spectrum disorder: Natural history and long-term outcome, an Indian experience.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity5697 :: ('MESH:D009188', 'Disease') :: ['transverse myelitis'] @entity1667 :: ('MESH:D008775', 'Chemical') :: ['methyl prednisolone'] @entity697 :: ('MESH:D000208', 'Disease') :: ['acute illness'] @entity17 :: ('MESH:D003711', 'Disease') :: ['demyelinating disorder'] @entity1652 :: ('MESH:D009471', 'Disease') :: ['Neuromyelitis optica', 'NMO'] @entity2744 :: ('MESH:C567425', 'Disease') :: ['endocrinopathy'] @entity15 :: ('MESH:D009103', 'Disease') :: ['multiple sclerosis'] @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids'] @entity3951 :: ('361', 'Gene') :: ['aquaporin 4'] @entity221 :: ('MESH:D005334', 'Disease') :: ['polyphasic illness'] @entity4685 :: ('MESH:D009187', 'Disease') :: ['myelitis']
@entity1652 :: (MESH:D009471,Disease) :: ['neuromyelitis']
